Cell & Gene Collaborative Blog

91. Your C&G Manufacturing Must-Reads (Super Mario Edition!) 3/11/2022

    This is a “permanent” copy of my C&G Manufacturing Must-Reads newsletter that was delivered on March 10. As March 10 is also known as Super Mario Day (Mar10), this Manufacturing Must-Reads has a Super Mario theme. 

92. From “Wild West” To “Rainforest”: Cell & Gene Manufacturing Ecosystem Embraces Symbiosis 2/28/2022

    We often affectionately refer to the CGT manufacturing sector as “The Wild West.” However, I’m also starting to see a subtle reformation happening — one that takes us beyond the barren desert full of dueling cowboys and heat-crazed goldminers to that of a lush, productive, and symbiotic rainforest.

93. Your C&G Manufacturing Must-Reads (Mixologist Edition!) 2/25/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

94. Lightning-Fast CMC Meets Incremental Innovation in Cell & Gene Therapy Manufacturing 2/24/2022

    I’ve heard it said that cell and gene therapy companies shouldn’t “let the perfect be the enemy of the good.” My conversation with Wugen’s VP of CMC, Ken Chrobak, was a fantastic example of how such a best practice can be translated into an actual CGT manufacturing program.

95. Beyond Cell Expansion: Building A Commercial CGT Manufacturing Framework 2/22/2022

    In the third of this four-part series, I transitioned my conversation with Ken Chrobak, Wugen’s VP of CMC, from the nuances of cell culture to the steps he and his team are taking to establish a consistent manufacturing framework that can span oceans and continents.

96. Zen & The Art Of Allogeneic NK Cell Therapy Manufacturing 2/17/2022

    Though my previous article with Ken Chrobak, VP of CMC for Wugen, highlighted which learnings could be taken from the autologous manufacturing space and applied to allogeneic therapies, we can’t overlook the layers of complexity that the cell type inherently throws into the manufacturing mix. 

97. Autologous Cell Therapy Learnings Illuminate The Path To Allogeneic Manufacturing Platforms 2/15/2022

    This is where Wugen's Ken Chrobak, VP of CMC, and I started our conversation — in what ways the autologous space has informed Wugen’s pursuit of allogeneic therapies, and how Chrobak and his team have implemented these learnings into the work they’re doing today.

98. ARW's C&G Manufacturing Must-Reads (Valentine's Day Edition!) 2/11/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

99. “Ancillary Materials” 1/25/2022

    I just couldn’t keep these links to myself

100. 5 New Year's Resolutions For Advancing The CGT Manufacturing Paradigm 1/25/2022

     The resolutions in this article provide some best practices we can implement and/or knowledge with which we can equip ourselves in the upcoming year. This way, in a year’s time when we look back on 2022, we will have a firm baseline from which we can measure just how much more sophisticated the CGT manufacturing sector has become.